INVO Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: INVO) on October 4, 2021, reporting an event that occurred on October 1, 2021. The company is incorporated in Nevada and its principal executive offices are located in Sarasota, Florida.
Key Financial Metrics
This filing reports a specific capital raise transaction rather than periodic financial performance metrics such as revenue, profit, or cash flow. The key financial details of the transaction are:
- Investor: Paradigm Opportunities Fund, LP (accredited institutional investor).
- Shares Issued: 600,703 shares of common stock.
- Purchase Price: $3.329 per share.
- Aggregate Purchase Price: $1,999,740.29.
- Closing Date: November 30, 2021.
- Break-up Fee: $250,000 payable by the breaching party if the transaction fails to close.
The filing text does not provide clear values for the company's current revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The material change reported is the entry into a Material Definitive Agreement (Stock Purchase Agreement) to raise approximately $2.0 million in equity capital. This represents a new financing arrangement rather than a change in operational performance compared to a prior period.
Guidance, Outlook, and Risks
Transaction Terms: The shares are being issued under the exemption from registration under Section 4(a)(2) and/or Rule 506 of the Securities Act of 1933. The investor has agreed to a 1-year lock-up period regarding the shares.
Risks and Contingencies: The agreement includes a $250,000 break-up fee contingent on either party failing to close the transaction. The filing does not provide specific management commentary on future guidance, operational outlook, or other risks beyond the terms of this specific agreement.
Investor Verification Checklist
- Verify the final closing of the transaction on November 30, 2021, and the actual receipt of the $1,999,740.29 proceeds.
- Confirm the issuance of the 600,703 shares and the updated share count.
- Review the full text of the Stock Purchase Agreement (Exhibit 10.1) for additional covenants or conditions not summarized in this report.
- Monitor compliance with the 1-year lock-up period by the investor.